+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 102 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating ODM-212, a drug being studied in a first-in-human, multi-site, open-label Phase 12 clinical trial involving adults with selected advanced solid tumors that cannot be treated with curative intent. The study aims to assess the safety and side effects of ODM-212 in patients who have cancers such as mesothelioma, lung carcinoma, colorectal cancer, and others with specific genetic alterations. This research is sponsored by Orion Corporation, Orion Pharma. Participants receive ODM-212 tablets at doses of 5mg andor 40mg. The study has two parts an initial dose escalation phase to find a safe dose, followed by a dose expansion phase that includes patients with solid tumors harboring specific genetic pathway alterations. Treatments are given orally, and dosing details are adjusted based on patient response and safety observations. During the study, participants will be monitored from the first dose until one year after the last study visit to track treatment-emergent adverse events and their severity. Regular assessments include physical exams, laboratory tests, and performance status evaluations. Participants must comply with the protocol and provide informed consent. The total study duration varies based on treatment and follow-up schedules.

Age: 18Years +All GendersPhase 1Phase 2
20 locations
O

Actively Recruiting

Researchers are evaluating patient characteristics, treatment patterns, and both short- and long-term outcomes in people with symptomatic obstructive hypertrophic cardiomyopathy HCM in the United States and Europe. The study focuses on patients receiving mavacamten, other treatments, or no treatment due to intolerance or previous treatment failure. The US sub-study particularly assesses mavacamtens safety, while the European sub-study evaluates both the safety and effectiveness of mavacamten in real-world settings. Participants receive treatment as prescribed by their physicians according to standard care for symptomatic obstructive HCM. One group takes mavacamten, while another receives beta-blockers, non-dihydropyridine calcium channel blockers, andor disopyramide. Some participants may be untreated due to intolerance or treatment failure. Treatments follow routine clinical care without study-driven changes. Throughout the study, participants are monitored for heart function changes, including heart failure events and left ventricular outflow tract gradients, over periods up to five years. Researchers collect data on arrhythmias, hospitalizations, mortality, and quality of life using questionnaires and biomarker tests. This observational registry captures real-world experiences to better understand treatment outcomes and patient health over time.

Age: 18Years +All Genders
101 locations
R

Actively Recruiting

This research aims to advance treatments for people with cystic fibrosis CF who do not take cystic fibrosis transmembrane conductance regulator CFTR modulators. It focuses on those genetically ineligible or not using these modulators, a group with different health challenges compared to most people with CF. The study seeks to collect detailed health data and specimens to support new therapy development and improve clinical trial designs for this underserved population. The study is observational and will follow participants over time, collecting research-quality CF outcome data aligned with clinical trial endpoints important for developing new therapies. Sub-studies will gather specialized measures to help evaluate safety and effectiveness of future treatments. Researchers also aim to understand research participation and engagement in this community. Participants will provide health information and samples during scheduled visits over at least 12 months. Researchers will monitor lung function using measures like ppFEV1, CFQ-R-RD scores, lung clearance index LCI, and mucociliary clearance MCC indices. The study will help characterize this CF group and support the development of innovative trials. It will also assess research involvement and provide data for comparison with new therapies.

Age: 12Years +All Genders
68 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
P

Actively Recruiting

Researchers are evaluating the best way to combine chemotherapy and radiation therapy for children and young adults with localized non-germinomatous germ cell tumors NGGCT in the brain. The study aims to optimize radiation treatment for patients who respond well to initial chemotherapy and to use higher dose chemotherapy followed by radiation for those who do not respond as well. This phase II trial focuses on how tumors respond to initial chemotherapy to decide the next treatment steps, aiming to reduce side effects and improve disease control. Participants receive induction chemotherapy with drugs like carboplatin, etoposide, ifosfamide, and thiotepa over up to six cycles, repeated every 21 days if no disease progression occurs. Based on their response, patients are assigned to one of two plans Plan A involves radiation therapy to the ventricles and spinal canal WVSCI, while Plan B includes high-dose chemotherapy with stem cell transplant followed by craniospinal radiation. Some patients may undergo second-look surgery to guide treatment decisions. During the study, participants have MRIs, cerebrospinal fluid and blood samples collected, and complete questionnaires assessing cognitive and behavioral functions. Researchers monitor tumor response, progression-free survival, overall survival, and side effects over up to 10 years. The study also compares outcomes based on radiation type and its effects on growth and blood counts, aiming to improve long-term quality of life for patients.

Age: 3Years - 29YearsAll GendersPhase 2
170 locations
E

Actively Recruiting

Researchers are evaluating combination chemotherapy treatments for patients with newly diagnosed diffuse anaplastic Wilms tumors DAWT and relapsed favorable histology Wilms tumors FHWT. This phase II trial aims to compare different chemotherapy regimens to see if adding drugs like vincristine and irinotecan improves survival outcomes for these patients, based on historical data. The study also explores kidney toxicity, genetic factors, and surgical outcomes related to these tumors. Patients are assigned to one of two treatment groups. Arm I Regimen UH-3 involves multiple cycles of vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan administered intravenously every 21 days with radiation therapy as needed. Arm II Regimen ICECycloTopo includes cycles of carboplatin, etoposide, ifosfamide, cyclophosphamide, and topotecan given intravenously every 21 days with surgery andor radiation as clinically indicated. Both groups undergo various imaging scans and biopsies throughout treatment. Participants are closely monitored with CT, PET, X-rays, MRI, ultrasound, bone scans, blood tests, and biopsies during the trial. After treatment, follow-up visits occur every 3 months for the first two years, then every 6 months for years 3 and 4, and once at year 5. The primary outcomes measured are event-free survival and overall survival up to five years. The study also collects blood, urine, and tumor tissue samples for future research and monitors treatment side effects and kidney function.

Age: 0 - 30YearsAll GendersPhase 2
205 locations
E

Actively Recruiting

Researchers are evaluating ifinatamab deruxtecan I-DXd, an antibody-drug conjugate, for treating children with relapsed or refractory solid tumors. These tumors are cancers mostly found in body organs and tissues, excluding blood cancers. The study aims to assess the safety and tolerability of I-DXd in children younger than 12 years and to see how many children experience tumor shrinkage or disappearance. The study has two parts Part 1 focuses on safety and determining the recommended dose, while Part 2 evaluates the treatments effectiveness. Participants receive I-DXd through an intravenous infusion on day 1 of every 3-week cycle. Treatment continues until disease progression or discontinuation. Part 1 evaluates safety and dose tolerability, and Part 2 expands to assess how well the treatment controls specific tumors such as osteosarcoma, neuroblastoma, rhabdomyosarcoma, and Wilms tumor. The study includes children from 1 month up to 18 years old, with specific criteria for each part. Throughout the study, participants undergo various assessments including monitoring for dose-limiting toxicities, adverse events, and tumor response over up to approximately 5 years. Researchers also measure drug levels in the blood and immune response to the drug. Participants will have regular evaluations to monitor safety and treatment effectiveness, with follow-up continuing after treatment ends to collect long-term data on outcomes and side effects.

Age: 1Month - 17YearsAll GendersPhase 1Phase 2
35 locations
S

Actively Recruiting

Researchers are investigating new treatments for children with hepatoblastoma, a common liver cancer in babies and very young children, and rhabdomyosarcoma RMS, a cancer that starts in muscle cells often found in the head and neck, bladder, arms, or legs. This study focuses on cases where these cancers have returned after treatment or did not respond to previous therapies. The research aims to understand the safety and behavior of a study drug called HER3-DXd patritumab deruxtecan in children and its effects on shrinking or eliminating cancer. Participants receive patritumab deruxtecan through an intravenous infusion on the first day of each 3-week cycle and continue until the cancer progresses or they stop the treatment. The study has two parts the first evaluates safety and determines the best dose, while the second assesses how well the drug works. This approach helps to find a safe and effective dose for children with these cancers. During the study, children will be closely monitored for side effects and treatment responses. Blood samples will be collected to study how the drug is processed in the body over time. Researchers will measure outcomes such as tumor response, time to response, and disease control for up to approximately five years. Participants will also be followed long-term to assess overall safety and effectiveness throughout the study period.

Age: 1Month - 17YearsAll GendersPhase 1Phase 2
64 locations
R

Actively Recruiting

Researchers are investigating whether adding intismeran autogene to pembrolizumab after surgery helps prevent cancer from returning in people with non-small cell lung cancer NSCLC whose tumors did not fully respond to treatment before surgery. This randomized phase 3 clinical trial compares pembrolizumab combined with intismeran autogene versus pembrolizumab with placebo in participants with resectable Stage II to IIIB NSCLC. The study focuses on individuals who have not achieved a complete pathological response after neoadjuvant therapy, aiming to improve disease-free survival. Participants receive neoadjuvant treatment consisting of pembrolizumab via intravenous infusion every 3 weeks for up to 4 cycles, combined with background chemotherapy chosen by the investigator. After surgery, the adjuvant treatment phase involves pembrolizumab given intravenously every 6 weeks for up to 7 cycles, plus either intismeran autogene or placebo administered by intramuscular injection every 3 weeks for up to 9 doses. The neoadjuvant phase lasts about 12 weeks, and the adjuvant phase extends up to approximately 42 weeks. During the study, participants will have regular assessments including monitoring for disease recurrence, survival, and quality of life using standardized questionnaires. Researchers will track adverse events and treatment tolerability throughout the trial, with follow-up lasting up to over 8 years to evaluate long-term outcomes. The main measurement is disease-free survival, with additional evaluations of overall survival, distant metastasis-free survival, and lung cancer-specific survival, along with patient-reported quality of life and safety data.

Age: 18Years +All GendersPhase 3
245 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of praliciguat in adults diagnosed with biopsy-confirmed focal segmental glomerulosclerosis FSGS, a kidney disease. This Phase 2, randomized, double-blind, placebo-controlled, multicenter study compares praliciguat to a placebo over an initial 24-week period, followed by an open-label phase where all participants receive praliciguat for another 24 weeks. Those who respond to treatment may join a long-term safety extension study. Participants are randomly assigned to receive either praliciguat or a matching placebo daily during the 24-week double-blind period. After this, all participants take praliciguat daily during the 24-week open-label period. Dose escalation to a target dose occurs during the initial treatment phase. Responders are invited to continue in a long-term safety extension where praliciguat is administered daily. During the study, participants undergo regular assessments including urine protein-to-creatinine ratio UPCR measurements, monitoring for treatment-emergent adverse events, and plasma concentration tests of praliciguat. Safety is closely tracked through reports of adverse events during both treatment periods and the long-term extension. The total participation duration may extend up to more than 48 weeks depending on extension study enrollment.

Age: 18Years +All GendersPhase 2
30 locations

1-10 of 102

1